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Abstract
Hepatitis B virus (HBV) is a global health threat, and its elimination by 2030 has been prioritised by the World Health
Organisation. Here we present an age-structured model for the immune response to an HBV infection, which takes into account
contributions from both cell-mediated and humoral immunity. The model has been validated using published patient data
recorded during acute infection. It has been adapted to the scenarios of chronic infection, clearance of infection, and flare-ups
via variation of the immune response parameters. The impacts of immune response exhaustion and non-infectious subviral
particles on the immune response dynamics are analysed. A comparison of different treatment options in the context of this
model reveals that drugs targeting aspects of the viral life cycle are more effective than exhaustion therapy, a form of therapy
mitigating immune response exhaustion. Our results suggest that antiviral treatment is best started when viral load is declining
rather than in a flare-up. The model suggests that a fast antibody production rate always leads to viral clearance, highlighting
the promise of antibody therapies currently in clinical trials.
Introduction
Hepatitis B virus (HBV) is a major global health problem with a high risk of causing chronic infection and death due to cirrhosis
and liver cancer. Despite pioneering use of recombinant DNA technology to create a safe and cheap prophylactic vaccine against
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HBV[ 1, 2 ] it is not universally deployed allowing the virus to infect 1.530 million people each year[ 3 ]. These add to the very
significant burden of the 2962 million chronically infected individuals, that are the consequence of the failure of their immune
systems to clear a primary infection[ 3 ]. Treatment of these patients relies on generic replicase inhibitors that rapidly elicit
resistance and interferon to boost antiviral responses. These treatments are largely ineffective leading to 82084,000 additional
HBV-related deaths annually, the largest cause of liver cancer worldwide[ 3 ]. HBV infected cells produce a significant excess of
non-infectious particles, such as subviral Dane particles (SVPs) that occur at 1000–100,000-fold higher concentration than the
infectious virion, allowing them to act as immune system decoys by sequestering antiviral antibodies[ 4, 5 ].
HBV infected individuals that mount an adequate immune response tend to clear the infection. During the early stages of the
infection the first contribution of the immune response comes from innate immunity which reduces viral spread and facilitates an
adaptive immune response. Adaptive immunity is made of two components, cell-mediated immunity (CD4  and CD8  T cells) and
humoral immunity (antibodies). CD4  T cells, also known as helper T cells, assist the activity of other immune cells by releasing
cytokines. CD8  T cells are not only responsible for killing of infected cells but also induce the noncytolytic “cure” of such cells
while antibodies neutralise virus particles and prevent infection of cells[ 6, 7 ].
Mathematical modelling provides new insights into the various aspects of viral infections and the impact of the immune response
on their clearance. Ciupe et al. presented a model to study the role of cytolytic and noncytolitic immune responses and the time lag
associated with effector cell activation and expansion during an acute HBV infection. It is hypothesised that cured cells and their
progeny are less likely to get infected, preventing reinfection[ 8, 9 ]. Later, Ciupe et al. looked into the dynamics of antibodies and
showed that retainingstill having a strong cell-mediated immune response is crucial for the control of early infection in
unvaccinated individuals[ 5 ]. Fatehi et al. developed a mathematical model to take into account contributions from innate and
adaptive immune responses, as well as cytokines. The model investigates the roles of different componentsparts of the immune
response on viral dynamics[ 10 ]. These models are based on systems of ordinary differential equations (ODE) or delay differential
equations (DDE). Nelson et al. presented an age-structured model of human immunodeficiency virus (HIV) infection to study the
impact of variations in the virion production rate and the death rate of infected cells over the course of the infection[ 11 ]. Although
age-structured models are more complicated, they can provide more realistic dynamics[ 12 ].
Experimental studies have shown that persistent stimulation of effector cells may result in immune impairment, e.g., immune
exhaustion[ 13, 14, 15 ]. In HBV infections, persistent antigen presentation by infected cells and exposure to high antigen loads
plays an important role in CD8  T cell exhaustion[ 16 ]. In order to analyse the impact of T cells exhaustion on viral dynamics,
Johnson et al. introduced a variable that captures the antigenic stimulus, called the level of exhaustion[ 17 ]. They assumed that T
cells are inactivated dependent on the level of exhaustion and modelled it as a Hill function with a half-maximal constant called the
exhaustion threshold. They showed that the exhaustion threshold has a significant impact on the ability of the immune response to
control an infection[ 17 ]. Later, Conway and Perelson included T cell exhaustion into an HIV infection model and showed that the
strength of cytotoxic T lymphocytes in killing productively infected cells, and the level of latently infected cells, determine the
post-treatment outcome of the infection[ 18 ].
We recently introduced a model of intracellular HBV infection dynamics and used it for comparative analysis of different
therapeutic strategies[ 19 ]. The model reveals a two-phase behaviour in the release of non-infectious SVPs. Shortly after infection,
a cell starts secreting SVPs. When the first intact virions are released, after 90 hours post-infection, SVP secretion stalls until the
onset of a second secretion phase. In order to analyse the impacts of this behavior on the immune response dynamics, and in
particular their interaction with anti-HBsAg antibodies, we have developed an age-structured model using infection kinetic
parameters derived from our intracellular model. This model has been parameterised such that its outputs fit data recorded from
patients undergoing an acute infection. We have adapted to the scenarios of a chronic infection, immune clearance of the infection,
and infection flare-ups via variation of the immune response parameters. The role(s) of cell-mediated and humoral immunity in an
acute HBV infection, including the effects of immune response exhaustion, have been analysed. The impacts of direct-acting
antivirals (DAA) treatments targeting various steps of the virus life cycle are compared to blocking T cells exhaustion, which is
known as exhaustion therapy. Optimal treatment regimes, such as the most effective treatment start times for the reduction of viral
load, have been identified. Our analysis highlights the potential benefit of antibody therapies currently in clinical trials, and allows
modelling of the impacts of DAAs under development.
Results
Model derivation
In order to analyse HBV infection dynamics with emphasis on highlighting the roles of the immune response, we developed a
detailed intercellular age-structured model of HBV infection. This model includes uninfected target cells, T(t), which are assumed
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structured by the age, a, sinceof infection. Therefore infected cells are denoted as, I(a, t)[ 11 ]. An infected cell produces complete
virions, which are infectious, and incomplete particles which occur in three distinct forms: RNA containing particles; empty
virions; and subviral particles (SVPs) which are either filamentous or spherical[ 4 ]. The release dynamics of these particles from
an infected cells has been studied precisely[ 19 ]. The variables  indicates the number of complete virions which infect target
cells at a rate . All types of incomplete particles are non-infectious and presentare covered with HBV surface antigens (HBsAg),
which enablinges them to act as decoys for the immune response by depletingconsuming HBsAg-specific antibodies, A(t). We
therefore onlyjust include the variable  into the model, which represents the total number of incomplete particles[ 4 ]. The
production rate of these particles depends on the age of an infected cell. The functions  and  show the production
profiles of complete and incomplete particles, respectively, from infected cells of age a[ 11 ]. We use the functions that are
presented in Fig. 2c of [ 19 ] as the base functions  and  (see Supplementary Fig. S1 online). Since it has been shown
that changing the intracellular model parameters will change the total number of released particles, we scale functions  and 
 bywith  and , respectively. We assume that  and  are the changeable parameters and fit them to patient data.
Complete and incomplete particles are cleared, based on their half-life, at rates  and . HBsAg-specific antibodies, which are a
component of the adaptive immune response called humoral immunity, are produced at rate  proportional to antigen load, and
are degraded at rate . We also add a logistic growth to the antibody equation, which is maintained through homeostatic
proliferation of memory B cells after infection. Antibodies can bind to complete and incomplete particles at rate  to create
complete virion-antibody complexes, , and incomplete particle-antibody complexes, , respectively. These complexes
disassociate at rate , or degrade at rate [ 5 ].  T he Please add a paragraph break in front of this sentence.
other component of anthe adaptive immune response is cell-mediated immunity. This, which occurs via the action of CD8  T
cells, also referred to as effector cells, E(t). These cells kill or cure infected cells. Since it has been hypothesised that cured cells
lose their resistance to productive infection at a slow rate of(in the order of  per day)[ 8 ], we model these two impacts in one
reaction, where effector cells remove infected cells at rate . Effector cells target infected cells in response to the display of viral
peptide-major histocompatibility complex (MHC) display on the cell surface, which is dependent on the expression of viral
proteins in the cells. As the intracellular model has shown, these viral proteins are produced and secreted shortly after infection.
We therefore assume that the removal rate of the infected cells is age-independent[ 19 ]. In additionMoreover, we assume infected
cells die at rate  due to infection or the action of the innate immune response, which is not included in the model directly[ 5, 10 ].
Effector cells are assumed to be produced at rate  and removed at rate  in the absence of infection[ 8 ]. During infection,
proliferation of effector cells happens in an infected cell density dependent manner with a time delay, i.e. it depends on the
density of antigen, withhere maximum proliferation rate is , and on , is the level of infected cells at which proliferation is half-
maximal[ 8, 17, 21 ]. It has been argued that persistent exposure to high antigen loads is associated with CD8  T cell exhaustion[
16 ]. Therefore, functional effector cells are lost at maximal rate , depending on the level of exhaustion, Q, which is
implemented as a Hill function with coefficient n and half-maximal constant [ 17 ]. The level of exhaustion, Q, is measured by
integrating over the antigenic stimulus ( ) times the parameter  which is called “blockade parameter”, and reduces
exponentially with coefficient , which is the rate of immune response recovery from exhaustion. The reduction of the blockade
parameter is assumed to simulate the blockade of interaction between the inhibitory receptor programmed death 1 (PD-1) and its
ligand (PD-L1) which restores CD8  T cell function[ 22 ].
Figure 1
The components and inferred interactions of the age-structured model of the immune response to an HBV infection ( 1 ), enabling
comparison of different treatment options. Blue and cyan circles show uninfected (T) and infected (I) cells, respectively, green circles
indicate the immune response (antibodies (A) and effector cells (E)), and gray circles show complete ( ) and incomplete ( ) viral
particles. Pink circles represent complete virion-antibody ( ) and incomplete particle-antibody ( ) complexes. Yellow shows the
level of exhaustion (Q). Double arrow-headed lines indicate natural clearance, bar-headed and single arrow-headed lines indicate
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1
With the above assumptions, the model, as illustrated in Fig. 1 , takes on the form Please align the = signs in the following equ
ation.
:
where  and .
All parameter descriptions and values adapted from the literature are presented in Table 1  together with a pointer to the
references they have been adapted from. The remaining parameters are estimated by fitting the model (Fig. 1 ).
Table 1
Overview of model parameters. Parameters that are fixed in the model are either adapted from the references indicated, or are fitted Please reorder
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the columns as follows. Naming the current order as 1 to 26, where 1 correspond to lambda and 26 to dq, please rearrange t
he rows according to the following sequence: 19,14,3,4,2,15,8,18,9,26,16,25,11,10,1,17,5,24,21,12,23,6,7,13,20,22
.
Parameter Description Value Reference
Target cells production rate [ 8, 23, 24 ]
d Death rate of target cells [ 20, 25 ]
Infection rate  (varies) –
Infected cells death rate  (varies) –
Removal rate of infected cells by effector cells  (varies) –
Rate modifying for virus production rate varies –
Rate modifying for incomplete particles production rate varies –
Virus clearance rate 0.67 [ 5 ]
Incomplete particles clearance rate 0.67 [ 5 ]
Antibody binding rate [ 5 ]
Antibody dissociation rate 10 [ 5 ]
Antibody production rate  (varies) –
Antibody proliferation rate  (varies) –
Antibody carrying capacity [ 5, 26 ]
Antibody degradation rate 0.033 [ 5 ]
Complexes degradation rate 2.7 [ 5 ]
Effector cells production rate 10 [ 9 ]
Removal rate of effector cells 0.5 [ 9 ]
Effector cells growth rate  (varies) –
Effector cells growth time delay  (varies) –
Hill function half-maximal constant for effector cells growth Fitting
Effector cells maximal exhaustion rate Fitting
Hill function half-maximal constant for effector cells exhaustion 10 [ 17 ]
n Hill function coefficient for effector cells exhaustion 3 [ 17 ]
Growth rate of exhaustion level 1 [ 17 ]
Reduction rate of exhaustion level 0.1 [ 17 ]
Within-host viral dynamics
The model (Fig. 1 ) was fitted to viral load data of viral loads from 6 patients who were recorded during the acute stage of
infection (Fig. 2 )[ 5, 8 ]. In this work, we also let the initial viral load ( ) be a variable. In patient number 2 (Fig. 2  P2) the
peak in viral load occurs earlier than in other patients, which shows the initial viral load could be higher in this patient. We
observe that for patient numbers 1, 3, 4, 5 and 6,  virion per ml as suggested by Ciupe et al.[ 5 ], but for patient
number 2  virions per ml. The parameter values derived from fitting of  are presented in Table 2 . Our model
captures the essential features of the viral loads in all patients, including the first rapid decline in the level of viral load after the
peak, followed by a slower decline, i.e. the biphasic viral decay afterfrom the peak[ 8 ]. In all patients viral load eventually
decreases to zero, matching the clinical outcomes in these patients with acute HBV infections.
The average fraction of infected cells at the peak of infection is around 74.547%, with a range of [60%-, 82%.] Thisthat is in good
agreement with previously estimated values[ 8, 9 ], and the experimental observation that more than 75% of hepatocytes were
λ 4 ×  per  ml 105
0.01 day−1
β  ml  day−1
δ  day−1
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hepatitis B core protein antigen positive ( ) in infected chimpanzees[ 6 ]. Previous models suggested that the level of
infected cells has a biphasic decline and decreases faster than the viral load[ 8, 9 ]. However, it has been observed that the level of
cccDNA (infected cells) has a slower decline compared with the level of free virus and remains detectable for more than two2
years after infection[ 27 ]. Our model predicts that infected cells decline slower compared with viral load (green lines Fig. 2 ), and
is in good agreement with Fig. 2 in Wieland et al.[ 27 ]. We fitted parameter values from Table 2  to a Gaussian distribution,
inferred 100 parameter sets and plotted the outcome for the 100 inferred parameter sets (see Supplementary Fig. S2 online).
Consistent with the fact that these patients are acute cases, we observe acute infection in 60% of the simulations, a periodic
solution in 25% of simulations, while the remainder exhibit a stable chronic infection steady state with a low level of free viruses




1 0.35 1.00 0.0130 8.50 2.50 3.00 0.366 2.20 6.50 0.33 0.29
2 3.57 2.00 0.0210 3 .00 0.70 1.00 0.550 1.50 4.50 10.00 0.14
3 1.20 0.90 0.0170 3.20 0.70 1.00 0.391 1.80 5.50 0.33 0.29
4 1.70 2.00 0.0400 3.00 0.70 1.00 0.370 1.80 5.00 0.33 0.24
5 1.30 1.80 0.0180 3.50 0.70 1.00 0.430 1.80 6.00 0.33 0.22
6 0.35 1.00 0.0130 8.50 2.50 3.00 0.366 2.20 8.70 0.33 0.13
Median 1.25 1.40 0.0175 3.35 0.70 1.00 0.381 1.80 5.75 0.33 –
Mean 1.41 1.45 0.0203 4.95 1.30 1.67 0.412 1.88 6.03 1.94 –
Std 1.19 0.54 0.0101 2.76 0.93 1.03 0.072 0.27 1.49 3.95 –
Figure 2
Paramaterising the model against patient data. The fitting of  as given by model (Fig. 1 ) (red line) to patient data ( ) indicates a
biphasic decline in viral load and sometimes a slower decline in the level of infected cells compared with virions (green line).
 HBcAg+
105
β × 10−9 μ × 10−4 δ ρ1 ρ2
pA
× 10−4
rA α τ (0)Vc
Vc ∙
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Adaptive immune response dynamics
The level of serum alanine aminotransferase (ALT) is used as proxy for the dynamics of effector cells in HBV infection[ 8, 9 ]. It
has been observed clinically that the peak in serum ALT occurs after the peak in viral load and the time lag between these two
peaks is 3–4 weeks[ 8, 28 ]. Our model also predicts that the average time lag in these 6 patients is 26.18 days (Fig. 3 ) which is in
a good agreement with previously reported values[ 8, 28 ]. We observe this delay in all patients (Fig. 3 ) and in our model (Fig. 4
c). This is due to the time lag in the production and activation of the effector cells and their propagation from lymph node to the
tissue. This delay creates a window of therapeutic  opportunity to start treatment with maximal effect while viral load is
decreasing and effector cells are approaching their maximal value. To provide a more realistic dynamic of effector cells we
included their exhaustion into our model. Supplementary Fig. S3 online indicates that in each patient the onset of exhaustion
coincides with a step increase in the level of effector cells. However, before the peak in exhaustion level, the immune response
controls the infection, so that the level of exhaustion starts declining before the peak of effector cells is reached.
Figure 3  indicates the level of antibodies against HBsAg (anti-HBsAg) in these patients. Anti-HBsAg levels  (
) are considered as negative[ 5, 29 ]. In unvaccinated patients, the level of antibodies is under 10 mIU/ml while
they are still classed as infected, i.e. their HBV-DNA test is positive[ 26 ]. Figure 3  shows that in all patients the level of
antibodies is well below 10 mIU/ml during the peak in viral load and the first phase of viral decline. Later, when the level of virus
has decreased significantly and effector cells are reduced to their basal level, it starts increasing but is still under 10 mIU/ml[ 26 ].
Figure 3
Time course of the immune response to the HBV infection in terms of effector cell and anti-HBsAg levels. The maximum in effector
cells (black curve) occurs 3–4 weeks after the peak in viral load. The red lines show the best fit to patient data, and the black dashed
lines show the level of anti-HBsAg in mIU/ml unit as predicted by the model (Fig. 1 ).
Figure 4
< 10 mIU/ml 
8.5 ×  mg/ml 10−4
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Stability analysis of the disease-free and chronic infection states, exemplified for different types of infection dynamics: acute
infections with immune clearance, and chronic infections with and without infection flare-ups. The parameters used are the median
values from Table 2 . The gray and yellow areas in (a) and (b) indicate the regions where the disease-free (DF) and chronic infection
(CI ) steady states are stable, respectively. Pink is the region where the system shows a stable periodic solution around a chronic
infection steady state (CI ). Solid and dashed lines indicate the boundaries of the steady-state and Hopf bifurcation, respectively, and
“fH” pinpoints the location of the fold-Hopf bifurcation. Stars indicate the points that are used for model simulations. (c) and (d)
correspond to an acute infection. , the maximum proliferation rate of effector cells, in (e) and (f) is reduced by 28% ( ),
indicating periodic oscillations around the chronic infection steady state (hepatitis flare). In (g) and (h),  is reduced by 56% (
), illustrating the case of a chronic infection.
Now we study the impact of varying immune response parameters on viral dynamics. We focus on parameters  (growth rate of
effector cells) and  (the rate at which functional effector cells are lost due to the exhaustion) in the cell-mediated immune
response which play crucial roles in the control of the infection[ 10, 28 ]. The other important parameter is the antibody
proliferation rate ( )[ 5 ]. Figure 4  shows the stability and instability regions of the disease-free and chronic infection states as a
function of these parameters. This figure shows that an increase in  always stabilises the disease-free state. However, when 
is low ( ), increasing  or decreasing  cannot stabilise the disease-free state, However, it destabilises the chronic steady
state due to a Hopf bifurcation, so one observes stable oscillations. Biologically, this is known asbehaviour is called “flare-ups”,
where through the interactions between viral infection and immune response we observe a periodic behaviour[ 10, 30, 31 ].
Examples of different types of infection dynamics are shown in Fig. 4  where Fig. 4 c and d indicate acute infection, Fig. 4 e and f
show a chronic infection with flare-ups, and Fig. 4 g and h show a chronic infection without flare-ups (stable chronic infection
steady state). Supplementary Fig. S4 online illustrates the impact of the time delay in effector cell activity ( ) and of the removal
rate of infected cells by effector cells ( ) on viral dynamics. Supplementary Figs. S4a and& b online indicate that a decrease in 
increases the stability range of the disease-free state with respect to  and , respectively. That is, following a decrease in , the
disease-free steady state will become stable for lower values of  and higher values of . Supplementary Fig. S4c online shows a
similar effect with respect to . This figure shows that an increase in  results in an increase in the stability range of the disease-
free state.
Effects of current clinical therapies
There are currently two approved anti-HBV therapies for clinical use. Interferon (IFN)-based therapy and nucleot(s)ide analogues
(NAs)[ 32 ], but more therapeutic strategies will be required to meet the Global WHO Challenge to make HBV infection a
treatable condition by 2030[ 16 ]. We recently compared current DAAs with several possible future treatment options using our
intracellular model[ 19 ]. The latter include capsid assembly modulators (CAMs), especially based on
heteroaryldihydropyrimidines HAPs[ 33 ]. Recently we showed that both HCV and HBV regulate the assembly of their
nucleocapsids around ssRNA forms of their genomes (e.g. the pgRNA of HBV) at least in part via sequence-specific core protein-
genomic RNA interactions at multiple sites, termed Packaging Signals (PSs)[ 34, 35, 36 ]. CAMs are at an advanced stage of
development[ 37, 38, 39 ], whilst the vital roles of PS-core interactions in HBV nucleocapsid assembly, and their targeting by small
s
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ligands are at a much earlier stage Please add a reference to: https://www.biorxiv.org/content/10.1101/2021.08.10.455820v1.
abstract
. The comparative analysis reveals strong potential synergistic effects between them. These treatment options reduce the viral
production rate and their effect is modelled by a factor , where  is the drug efficacy and its value is constant
from the start of the treatment untiltill its removal[ 20, 40 ]. This method hasis also been used in the context of other viruses[
41, 42, 43, 44, 45 ]. IFN-based therapy and CAMs also block de novo infections[ 10, 46 ]. Mathematically, one can represent this
effect by a modified transmission rate , where  is the drug efficacy[ 10, 19 ]. Here we refer to these types of
treatments as antiviral therapy. The other suggested form of therapy is the recovery of the CD8  T cells from exhaustion
(exhaustion therapy)[ 16 ]. The impact of this treatment option can be modelled by a modified blockade parameter , where
 is the efficacy of the treatment[ 22 ]. The new equations take the following form:
The total drug effectiveness , which is defined as , will allows us to determine a critical drug
efficacy, , where the infection gets cleared for [ 10, 47 ].
IFN-based therapy, which results in higher rates of hepatitis B e antigen (HBeAg) and HBsAg loss compared with NA therapy, is
usually administered for around 48 weeks[ 32 ]. Thus, 48 weeks after the start of treatment we remove its effect on the model to
determine the efficacy required to avoid a viral rebound after the removal of treatment. This will help us to find an optimal
efficacy that a new therapy should have to be effective, thus addressing an urgent need identified by Lok et al.[ 32 ]. Figure 5
shows the impact of starting antiviral therapy at different times post infection. In Fig. 5 a treatment start is 130 dpi, while in Fig. 
5 b it is 150 dpi. These figures indicate that in a region where the system shows a periodic behaviour, an earlier treatment start
during the declining phase of the viral dynamics is more effective than a treatment start during the increasing phase or around the
peak of a flare-up (Figs. 5 c and d, verified explicitly for treatment start one week before, and after, and the top of the peak). This
indicates the co-existence of the disease-free steady state and stable periodic oscillations around the chronic infection steady state,
so that depending on the initial conditions the system can either converge to the disease-free case or exhibit a periodic behaviour.
Thus, starting treatment at different times can lead to different outcomes. Supplementary Video S1 online shows the minimal total
efficacy ( ) that is required to clear the infection following a 48- weeks ofs therapy starting at various times between 50 dpi
(representing an early detection of the infection) to 160 dpi (representing a late detection of the infection). It indicates that
treatment start at 50-80 dpi (around a month before the first viral peak) is most effective. It also shows that treatment start at 90-
120 dpi (close to the first viral peak) is not that effective, in particular when the chronic steady state is stable. After the first viral
peak, if the chronic steady state is stable, the treatment start time is not important as the infection is in a stable state. However, in
the case of a periodic solution, starting treatment when the viral load is declining requires a treatment of lower efficacy than
would be necessary to achieve the same outcome for a treatment start in the increasing phase. These results indicate that a decline
in the level of free virus in a patient, can be a sign of an acute infection, or correspond to the declining phase before a flare-up.
Therefore, it is crucial to start the treatment, rather than wait to start it after the flare-up. Supplementary Video S2 online shows
the minimal efficacy required to clear the infection following 48 weeks of exhaustion therapy starting at in between 50 dpi and
160 dpi. Surprisingly, it shows that this treatment is not as effective as antiviral therapy targeting the viral life cycle and the
treatment start point has no significant impact on the outcome. Moreover, our model does not show any significant synergistic
effects between these two treatment options. This can be seen from the fact that this treatment option is only effective in a small
area of the -  parameter plane, corresponding to an area in which antiviral therapy targeting the viral life cycle is also effective
even for low drug efficacy.
Figure 5
Start of antiviral therapy when viral load is in a declining phase is more effective. (a) and (b) show the minimal total efficacy ( )
that is required to clear the infection following a 48- weeks of therapy starting at 130 and 150 days post infection (dpi), respectively.
The white area indicates a stable disease-free state. The red solid curves indicate the onset of the steady-state bifurcation, whereas the
red dotted lines of the Hopf bifurcation of the chronic state. The black hatched area indicates the region where an efficacy of 
 is ineffective. The black star (indicated with an arrow) shows the point at which the numerical simulations ((c) 
and (d) ) have been performed. Magenta and brown vertical lines indicate the start and end of treatment, respectively. The
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dashed and dotted lines, represent the effects of treatments on viral load, for treatment startings 130 orand 150 dpi, respectively.
In Fig. 5  we consider a constant treatment efficacy for the full duration of the treatment, as is typically done in viral infection
models[ 20, 40, 41, 42, 43, 44, 45 ]. However, in Supplementary Figs. S5 and S6 online we study the impact of a periodic
administration of antiviral treatments of different intensities (efficacies), including also the option of zero efficacy to model the
absence of treatment in one of the treatment periods, to find possible synergistic effects for alternating treatments. We consider
treatment starts at 130 and 150 dpi, respectively, and different combinations of treatment periods, i.e. a treatment with total
efficacy  in period 1 is followed by a treatment with total efficacy . Then this scheme is repeated for 48 weeks, which is the
recommended time for administration of an HBV therapy[ 32 ]. Supplementary Fig. S5 online indicates that alternating antiviral
therapy with a total efficacy of 90% for 4 weeks, with 4-week intervals of no treatment over 48 weeks leads to clearance of the
infection. To understand the dynamical reason for this, we checked viral load 28 days post treatment stop. We observed that it is
below the level of virus in the drug-free (control) case at 186 dpi (130+56) and is in a declining phase. Although for treatment
start at 150 dpi the results are more chaotic (see Supplementary Fig. S6 online), cases leading to clearance of the infection show
similar behaviour as for the 130 dpi case. Supplementary Fig. S7 online shows the impact of a treatment start at 150 dpi, with
periodic administration of antiviral treatments of different efficacy in 4 weeks intervals. This figure shows that in successful cases
antiviral treatment is administered during the declining phase of viral load. This is consistent with the main conclusion from our
modelling of constant treatment efficacies above, that also shows that the outcome of a treatment depends highly on a start time in
the declining phase of viral load. Although Supplementary Figs. S6 and S7 online indicate that drug administration in various
efficacies and periods can sometimes lead to clearance of the infection, establishing these time periods and efficacies in a patient
is not practicable in the clinics. To address this issue, we studied the impact of a treatment start at each day in one period of the
viral load dynamics (i.e. each day from 130 to 212 dpi, covering 83 possible start times). In each case, we either consider a
constant efficacy, or a periodic efficacy where the treatment is administeredon for 28 days and then withheldoff for 28 days. We
chose an 28-day periodicity as this is optimal according to Supplementary Figs. S5 and S6 online. This shows that for a total
treatment efficacy of 99% a constant treatment will always leads to viral clearance. However, if the total efficacy is only 90% then
a constant treatment is successful only at 52 treatment start times i.e., the chance of having a successful outcome is 62.65%. By
contrast, a periodic treatment would increase the chance of success to 96.38%. It is worth noting that all currently available
treatments for HCV have an efficacy of more than 99%[ 20 ]. Also CAMs and the PS-targeting drugs for HBV, which are under
development, have shown promising outcomes with efficacies of more than 95%[ 19 ]. Thus, our analysis suggests that a non-
periodic treatment option, in line with those previously administered for HBV and other viral infections, appears to be a
reasonable strategy. However, different strategies should be tested in clinical trials, as our modelling indicates that under certain
circumstances periodic treatment options can be superior.
ε1 ε2
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Monoclonal anti-HBsAg antibody drugs are currently being investigated in clinical trials as a treatment against HBV infections[
48, 49, 50 ]. To study the impact of this treatment option we extended our model, modelling these antibodies as an influx into the
system (see Supplementary Section S1 online). Supplementary Fig. S8 online indicates that the impact of monoclonal antibody
therapy is independent of the treatment start time, leading to clearance of the infection in both the declining and the increasing
phase.
Discussion
In this paper we derivehave developed an age-structured model for the immune response to HBV infections. It is based on the
particle release profiles from a detailed intracellular model[ 19 ]. Our age-structured model focuses on two components of the
adaptive immune response known as humoral (antibodies) and cell-mediated (CD8  T cells) immunity. To provide more realistic
viral dynamics and robust predictions, we fitted our model to patient data. Patient data indicate a biphasic decrease in the viral load
which is well captured well by the model. Previous models have predicted that the number of infected cells declines faster than
viral load[ 8, 9 ], but it has been shown clinically that the level of cccDNA (infected cells) has a slower decay compared with the
viral load[ 27 ]. Interestingly, our model reflects this trend. Regarding the dynamics of the immune response, our model shows that
the peak in the level of effector cells occurs around 26 days after the peak in viral load, which is in good agreement with previously
reported values[ 8, 28 ]. The antibody level stays well under 10 mIU/ml during the peak and the first phase of viral decline. Later, it
starts increasing, but it remains under 10 mIU/ml[ 26 ].
We also performed a stability analysis of the model to study the impact of varying parameter values on the outcome of the
infection. The model suggests that increasing  (the proliferation rate of antibodies) always stabilises the disease-free state. When
 is low, decreasing  (the rate at which functional effector cells are lost due to exhaustion) or increasing  (expansion rate of
effector cells) will not stabilise the disease-free state, but the chronic steady state loses its stability and one observes stable
oscillationss. Biologically, this behaviour is called “flare-ups”[ 10, 30, 31 ]. Therefore, our model illustrates the importance of the
humoral immunity in viral clearance.
Current therapeutic strategies either block the formation of new virions and viral entry (antiviral therapy) or recover the exhausted
CD8  cells (exhaustion therapy). We used our model to compare the impacts of these different treatment options. Our results
suggest that exhaustion therapy is not as effective as antiviral therapy, and that the start of treatment does not have a significant
impact on the outcome of exhaustion therapy. However, the timing of treatment start plays a crucial role in the outcome of antiviral
therapy. Our model shows that around one month before the peak in viral load would be the best time to start antiviral therapy,
illustrating the importance of identifying cases early into an infection. Since this is not always practicable, we also analysed the
impact of a treatment start later during infection. Whilst treatment start time is not significant in the context of stable chronic
steady states, it matters for periodic solutions, where a treatment start during the declining phase of viral load is more effective. As
declining levels of free virus in a patient can indicate the declining phase before a flare-up, it is crucial to start treatment
immediately rather than wait until after a flare-up. Our model moreover illustrates that antibodies play an important role in
suppression of viral load, supporting strategies to use monoclonal antibodies as therapy against chronic Hepatitis B viral infections.
Indeed, monoclonal anti-HBsAg antibody drugs are currently investigated in clinical trials[ 48, 49, 50 ], and our model suggests that
they should be highly efficient ways of combating chronic hepatitis B.
One critical hurdle to such developments has been the restriction of HBV infection to people and other higher primates, restricting
the rapid development of new drugs in animal models. The development of humanised transgenic mice, available with and without
a human immune system, will hopefully permit much faster experimental development[ 51, 52 ]. This model and others will be
useful for the evaluation of any novel therapeutic strategies being developed.
Methods
Patient data
Our study uses patient data comprising 6 patients whose their viral loads were recorded during the acute stage of infection and are
reported in Ciupe et al.[ 5, 8 ], Webster et al.[ 28 ] and Whalley et al.[ 53 ]. Patients 1, 2, 4, and 6 are female with an age range of
37 to 71. The data are published in the Supporting Information of Ciupe et al.[ 5 ].
Parameter estimation
It has been estimated that the total number of liver cells in an adult is equal to  and only 60% of them are hepatocytes[
8, 23, 54, 55 ]. We assume that there are 3 liters of serum in an adult, containing complete and incomplete particles[ 24 ].
Therefore, . The death rate of target cells is estimated to be [ 20, 25 ], so 






λ/d = 0.6 × 2 × /3000 = 4 ×  cells/ml 1011 107 0.01 day−1
λ = 4 × 105
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[ 26 ], we assume that . For parameters 
 (the level of infected cells at which growth is half-maximal) and  (the rate at which functional effector cells are lost due to
exhaustion) various fixed values have been determined previously[ 17, 18 ]. We thus set  and . These
values provide a good fit to the viral load data. All parameter values adapted from the literature are presented in Table 1  together
with a pointer to the reference they have been adapted from. The remaining parameters are estimated by fitting the model (Fig. 1 )
to the viral load data using a modified version of DKLAG6 for the numerical simulations of the model (Fig. 1 ) in Fortran (see
www.radford.edu for more detail)[ 56 ] and an implementation of the Nelder-Mead algorithm in Fortran (see people.sc.fsu.edu for
more detail)[ 57 ]. More details about the method are provided in the supplementary materials online (see Supplementary Section
S2 online).
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